The Expanding Role of Angiotensin Converting Enzyme Inhibitors in the Management of Hypertension
- 1 April 1995
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 35 (4), 337-342
- https://doi.org/10.1002/j.1552-4604.1995.tb04070.x
Abstract
Angiotensin converting enzyme (ACE) inhibitors are increasingly important in antihypertensive therapy because of their efficacy, tolerability, and specific benefits in subsets of patients. They are pharmacologically diverse. Whereas most benefits have been proven with older agents (captopril, enalopril), newer agents, such as benazepril, quinapril, and ramipril, offer potential advantages that remain to be proven.Keywords
This publication has 45 references indexed in Scilit:
- Angiotensin Converting Enzyme InhibitorsAmerican Journal of Hypertension, 1990
- Controlled clinical trials of drug treatment for hypertension. A review.Hypertension, 1989
- Quinapril—A Preclinical Review of the Pharmacology, Pharmacokinetics, and ToxicologyAngiology, 1989
- Converting-Enzyme Inhibitors in the Treatment of HypertensionNew England Journal of Medicine, 1988
- Lisinopril in hypertensive patients with and without renal failureEuropean Journal of Clinical Pharmacology, 1987
- Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertensionClinical Pharmacology & Therapeutics, 1984
- Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril.Circulation, 1981
- The antihypertensive effect of captopril. Evidence for an influence of kinins.Hypertension, 1980
- Haemodynamic Effects of Captopril in Hypertensive Patients: Comparison with SaralasinClinical Science, 1979
- Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive PatientsAnnals of Internal Medicine, 1979